Gruber H E, Ivey J L, Baylink D J, Matthews M, Nelp W B, Sisom K, Chesnut C H
Metabolism. 1984 Apr;33(4):295-303. doi: 10.1016/0026-0495(84)90187-2.
Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis. All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd. The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline. Although mean total body calcium (TBCa) was not significantly different between treated and control patients throughout the study, mean differences in the change in TBCa from baseline (treated minus control) were significant at 12, 18, and 26 months. The mean slope of TBCa for treated patients, but not for controls, was significantly positive through 18 months. Iliac crest bone biopsies showed (1) a significantly greater percent total bone area in treated compared to control patients at 2 years, and (2) a significantly decreased percent resorbing surface in treated patients when evaluated by paired difference from baseline. At 4 months, serum calcium values were significantly lower in treated patients than in controls (mean difference, treated minus controls), but were not statistically different from controls at study completion. Urine calcium increased significantly for the first 4 months in treated subjects and then declined to baseline levels. Since urinary calcium increased, the increase in TBCa was probably associated with an increase in net intestinal calcium absorption.
本文展示了一项为期两年的对照研究结果，该研究评估了每日100单位合成鲑鱼降钙素治疗绝经后骨质疏松症的疗效。所有患者均口服维生素D2 400单位/天及碳酸钙1200毫克/天。21名对照患者和24名治疗患者（平均年龄65岁）在基线时无统计学差异。尽管在整个研究过程中，治疗组和对照组患者的平均全身钙（TBCa）无显著差异，但治疗组与对照组相比，TBCa自基线起变化的平均差异在第12、18和26个月时具有统计学意义。治疗组患者TBCa的平均斜率在18个月内呈显著正增长，而对照组则无此现象。髂嵴骨活检显示：（1）在两年时，治疗组患者的总骨面积百分比显著高于对照组；（2）通过与基线进行配对差异评估，治疗组患者的骨吸收表面百分比显著降低。在第4个月时，治疗组患者的血清钙值显著低于对照组（治疗组减去对照组的平均差异），但在研究结束时与对照组无统计学差异。治疗组受试者在最初4个月内尿钙显著增加，随后降至基线水平。由于尿钙增加，TBCa的增加可能与肠道净钙吸收增加有关。
